Key molecule for flu infection identified

May 30, 2018, Hokkaido University
Changes in body weight after IAV infection. Mice untreated with CCB died within five days after IAV infection while the group treated with CCB (diltiazem) survived and recovered their body weights, as did a common anti-flu drug oseltamivir-treated group. Credit: Fujioka Y. et al., Cell Host

After decades of research, a research team has discovered the key receptor molecule that enhances the infection of the influenza A virus, providing a novel target for anti-flu drug development.

Viral infection starts when a particle attaches to a receptor molecule on the surface of a host cell. The virus particle then hijacks cellular machinery to enter the cell and replicate itself, establishing the infection. The key receptor molecule for the influenza A virus (IAV) has remained unidentified despite decades of research.

A research team led by Professor Yusuke Ohba of Hokkaido University previously demonstrated that changes in Ca2+ concentration in host cells play an important role in IAV infections.

In the latest study published in Cell Host & Microbe, the team has discovered that the Ca2+ channel, a transmembrane protein that allows Ca2+ to move across the cell membrane, is the key receptor molecule for IAV infections. Furthermore, treating human cells with calcium channel blockers (CCBs), which are commonly used as anti-hypertension , significantly suppressed IAV infections.

In experiments using cultured human , the team found that IAV binds to the Ca2+ channel on the cell's surface to trigger an influx of Ca2+, followed by entry of the virus and . Knocking down Ca2+ channels inhibited IAV-induced Ca2+ influx and virus entry. They also revealed that sialic acid on the Ca2+ channel is crucial for the virus to bind.

Human bronchial epithelial cells cultured with (right) or without (left) a calcium channel blocker (CCB) prior to exposure to IAV. Red signals show infected and replicated IAV. Treatment with CCB significantly suppressed IAV infections. Credit: Fujioka Y. et al., Cell Host

Finally, the team tested the effect of CCB on IAV infections using mice. When they treated the animals with CCB intranasally, a significant and dose-dependent reduction in the amount of replicated viruses was observed. When the animals were treated with high amounts of IAV, administration of CCB significantly prolonged survival and allowed weight recovery of the survivors whereas the untreated group died within five days.

"There were cases when the suppressive effect of CCB on IAV infections was comparable to that of an existing anti-flu drug. We expect that the interaction between IAV and the Ca2+ channel could be a novel and important target for future drug development," says Yusuke Ohba.

Credit: Hokkaido University

Explore further: Ebola virus exploits host enzyme for efficient entry to target cells

More information: Yoichiro Fujioka et al. A Sialylated Voltage-Dependent Ca 2+ Channel Binds Hemagglutinin and Mediates Influenza A Virus Entry into Mammalian Cells, Cell Host & Microbe (2018). DOI: 10.1016/j.chom.2018.04.015

Related Stories

Ebola virus exploits host enzyme for efficient entry to target cells

February 7, 2018
Researchers have identified a key process that enables the deadly Ebola virus to infect host cells, providing a novel target for developing antiviral drugs. The Ebola virus incorporates a cellular enzyme into its virus particles, ...

Male hormones may promote infection by virus that causes Kaposi's sarcoma

September 28, 2017
Male hormones may facilitate infection with a virus that can cause a type of cancer known as Kaposi's sarcoma. This finding, published in PLOS Pathogens by Ke Lan's group of the State Key Laboratory of Virology, Wuhan University, ...

Recommended for you

Breakthrough in designing a better Salmonella vaccine

September 24, 2018
UC Davis researchers announce in the Proceedings of the National Academy of Sciences this week a breakthrough in understanding which cells afford optimal protection against Salmonella infection—a critical step in developing ...

Antifungal agent found to be possible treatment for porphyria

September 24, 2018
A large team of researchers from Spain, France and the U.S. has found that a common antifungal agent might be useful as a treatment for a rare type of porphyria. In their paper published in the journal Science Translational ...

New findings on the muscle disease Laing early-onset distal myopathy

September 24, 2018
New avenues are now being opened toward treatment of Laing distal myopathy, a rare disorder that causes atrophy of the muscles in the feet, hands and elsewhere. In a study published in the journal PNAS, researchers have identified ...

Insulin shows great potential against chronic colitis

September 24, 2018
Diabetes is not the only disease on which insulin has an effect, it appears. In a new study using tests on mice, researchers from the University of Copenhagen, among others, have discovered a new method for treating chronic ...

A new approach to developing a vaccine against vivax malaria

September 21, 2018
A novel study reports an innovative approach for developing a vaccine against Plasmodium vivax, the most prevalent human malaria parasite outside sub-Saharan Africa. The study led by Hernando A. del Portillo and Carmen Fernandez-Becerra, ...

Pre-clinical success for a universal flu vaccine offers hope for third generation approach

September 21, 2018
Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Communications.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.